Loading...
Market
Tezspire's impact on Amgen's revenue growth for fiscal year 2025
2
Resolution / Starting Odds
Less than 5% increase • 25%
5% to 10% increase • 25%
10% to 15% increase • 25%
More than 15% increase • 25%
Amgen's fiscal year 2025 financial reports
Story
Amgen and AstraZeneca Report Positive Phase 3 WAYPOINT Results for Tezspire in CRSwNP, Meeting Primary Endpoints
Nov 8, 2024, 07:11 AM
Amgen and AstraZeneca have announced positive top-line results from their Phase 3 WAYPOINT trial evaluating Tezspire for the treatment of adults with chronic rhinosinusitis with nasal polyps (CRSwNP). The trial met both co-primary endpoints, demonstrating a statistically significant reduction in nasal polyp size. This marks a significant advancement in treatment options for patients suffering from this condition. The companies' stocks, $AMGN and $AZN, are likely to be impacted by this development.
View original story
Similar markets
Increases revenue by more than 5% • 25%
Increases revenue by up to 5% • 25%
No significant impact on revenue • 25%
Decreases revenue • 25%
Exceeds forecasts • 25%
Meets forecasts • 25%
Below forecasts • 25%
Significantly below forecasts • 25%
Stock price increases by more than 10% • 25%
Stock price remains within +/- 10% range • 25%
Stock price decreases by more than 10% • 25%
Stock price fluctuates but ends within +/- 5% range • 25%
Less than 10% • 25%
10% to 20% • 25%
21% to 30% • 25%
More than 30% • 25%
Less than $50 million • 25%
$50 million to $100 million • 25%
$100 million to $150 million • 25%
More than $150 million • 25%
Less than $500 million • 25%
$500 million to $1 billion • 25%
$1 billion to $1.5 billion • 25%
More than $1.5 billion • 25%
Less than $10 billion • 25%
$10 billion to $20 billion • 25%
$20 billion to $30 billion • 25%
More than $30 billion • 25%
Below $100 million • 25%
$100 million to $500 million • 25%
$500 million to $1 billion • 25%
Above $1 billion • 25%
More than 20% increase • 25%
10%-20% increase • 25%
0%-10% increase • 25%
Decrease • 25%
